NCT03998384

Brief Summary

This study is designed to assess and to evaluate the therapeutic effect of retrobulbar injection of autoserum in the treatment of retinitis pigmentosa.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2020

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2019

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 26, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

January 1, 2020

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

June 26, 2019

Status Verified

June 1, 2019

Enrollment Period

3 years

First QC Date

June 7, 2019

Last Update Submit

June 25, 2019

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change of the visual acuity

    To measure the visual acuity with logarithmic visual chart.

    one day before injection, one day, one month, three months and six months after surgery

  • Change of the contrast sensitivity

    To access the change of contrast sensitivity in different special frequency.

    one day before injection, one month, three months and six months after surgery

  • Change of the electrophysiological detection (flash electroretinogram)

    To evaluate the retinal function with the use of flash electroretinogram (F-ERG).

    one day before injection, three months and six months after surgery

  • Change of the electrophysiological detection (electro-oculogram)

    To evaluate the retinal function with the use of electro-oculogram (EOG)

    one day before injection, three months and six months after surgery

Study Arms (2)

group of autoserum

ACTIVE COMPARATOR

One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.

Procedure: retrobulbar injection of autoserum

group of placebo

PLACEBO COMPARATOR

The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.

Procedure: retrobulbar injection of placebo

Interventions

Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.

group of autoserum

Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison

group of placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Clinical diagnosis of retinitis pigmentosa

You may not qualify if:

  • Suspected glaucoma, suspected optic nerve disease, blindness due to other ocular disease
  • Combined with serious systemic disease
  • Can not cooperate with the interventions and examinations.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Retinitis Pigmentosa

Condition Hierarchy (Ancestors)

Eye Diseases, HereditaryEye DiseasesRetinal DystrophiesRetinal DegenerationRetinal DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Hongxia Wang, MD

CONTACT

Wensheng Li, MD,PHD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Two eyes of one patient with RP will be divided into two groups. One eye with more serious retinal atrophy will receive retrobulbar injection of autoserum, and the other eye will receive retrobulbar injection of saline solution.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 7, 2019

First Posted

June 26, 2019

Study Start

January 1, 2020

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

June 26, 2019

Record last verified: 2019-06